Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Justin StebbingYauheni V BaranauValery BaryashAlexey ManikhasVladimir MoiseyenkoGiorgi DzagnidzeEdvard ZhavridDmytro BoliukhJoanna PikielAlexandru E EniuRubi K LiBeatrice TiangcoSang Joon LeeSunghyun KimPublished in: Breast cancer research and treatment (2021)
The similarity of the time-to-event analyses between CT-P6 and trastuzumab supports the equivalence in terms of efficacy established for the primary endpoint. CT-P6 was well tolerated, with comparable safety and immunogenicity to trastuzumab. ClinicalTrials.gov: NCT02162667 (registered June 13, 2014).
Keyphrases
- phase iii
- image quality
- dual energy
- epidermal growth factor receptor
- computed tomography
- contrast enhanced
- open label
- clinical trial
- early breast cancer
- phase ii
- metastatic breast cancer
- positron emission tomography
- magnetic resonance imaging
- double blind
- placebo controlled
- randomized controlled trial
- tyrosine kinase